These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

516 related items for PubMed ID: 12695731

  • 21. Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model.
    Santen G, Danhof M, Della Pasqua O.
    J Psychiatr Res; 2008 Oct; 42(14):1189-97. PubMed ID: 18353370
    [Abstract] [Full Text] [Related]

  • 22. [Clinical studies: the missing antidepressants].
    Faludi G.
    Neuropsychopharmacol Hung; 2005 Sep; 7(3):103-4. PubMed ID: 16493873
    [No Abstract] [Full Text] [Related]

  • 23. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks' duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach.
    Tedeschini E, Fava M, Papakostas GI.
    J Clin Psychiatry; 2011 Jan; 72(1):98-113. PubMed ID: 21208576
    [Abstract] [Full Text] [Related]

  • 24. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 25. Meta-analysis of the placebo response in antidepressant trials.
    Rief W, Nestoriuc Y, Weiss S, Welzel E, Barsky AJ, Hofmann SG.
    J Affect Disord; 2009 Nov; 118(1-3):1-8. PubMed ID: 19246102
    [Abstract] [Full Text] [Related]

  • 26. [Placebo-controlled antidepressant drug trials. Considering the ethical implications].
    Deisenhammer EA, Hinterhuber H.
    Fortschr Neurol Psychiatr; 2003 May; 71(5):243-8. PubMed ID: 12740755
    [Abstract] [Full Text] [Related]

  • 27. Crocus sativus L. in the treatment of mild to moderate depression: a double-blind, randomized and placebo-controlled trial.
    Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah-Pour H, Jamshidi AH, Khani M.
    Phytother Res; 2005 Feb; 19(2):148-51. PubMed ID: 15852492
    [Abstract] [Full Text] [Related]

  • 28. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW, Gueorguieva RV, Baker CB, Makuch RW.
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [Abstract] [Full Text] [Related]

  • 29. Worsening of depressive symptoms prior to randomization in clinical trials: a possible screen for placebo responders?
    Evans KR, Sills T, Wunderlich GR, McDonald HP.
    J Psychiatr Res; 2004 Sep; 38(4):437-44. PubMed ID: 15203296
    [Abstract] [Full Text] [Related]

  • 30. The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences.
    Hegerl U, Mergl R.
    J Psychopharmacol; 2010 Apr; 24(4):445-8. PubMed ID: 19825901
    [Abstract] [Full Text] [Related]

  • 31. Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials.
    Soares CN, Kornstein SG, Thase ME, Jiang Q, Guico-Pabia CJ.
    J Clin Psychiatry; 2009 Oct; 70(10):1365-71. PubMed ID: 19906341
    [Abstract] [Full Text] [Related]

  • 32. Double-blind, placebo-controlled, fixed dose trial of minaprine in patients with major depression.
    Amsterdam JD, Dunner DL, Fabre LF, Kiev A, Rush AJ, Goodman LI.
    Pharmacopsychiatry; 1989 Jul; 22(4):137-43. PubMed ID: 2668978
    [Abstract] [Full Text] [Related]

  • 33. Efficacy issues with antidepressants.
    Fawcett J, Barkin RL.
    J Clin Psychiatry; 1997 Jul; 58 Suppl 6():32-9. PubMed ID: 9227671
    [Abstract] [Full Text] [Related]

  • 34. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury.
    Ashman TA, Cantor JB, Gordon WA, Spielman L, Flanagan S, Ginsberg A, Engmann C, Egan M, Ambrose F, Greenwald B.
    Arch Phys Med Rehabil; 2009 May; 90(5):733-40. PubMed ID: 19406291
    [Abstract] [Full Text] [Related]

  • 35. Study designs and outcomes in antidepressant clinical trials.
    Khan A, Schwartz K.
    Essent Psychopharmacol; 2005 May; 6(4):221-6. PubMed ID: 16041918
    [Abstract] [Full Text] [Related]

  • 36. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: a meta-analysis.
    Iovieno N, Papakostas GI.
    J Clin Psychiatry; 2012 Oct; 73(10):1300-6. PubMed ID: 23140647
    [Abstract] [Full Text] [Related]

  • 37. Placebo response in generalized anxiety: its effect on the outcome of clinical trials.
    Schweizer E, Rickels K.
    J Clin Psychiatry; 1997 Oct; 58 Suppl 11():30-8. PubMed ID: 9363046
    [Abstract] [Full Text] [Related]

  • 38. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR.
    J Clin Psychiatry; 1997 Oct; 58 Suppl 5():15-23. PubMed ID: 9184623
    [Abstract] [Full Text] [Related]

  • 39. Frequency of positive studies among fixed and flexible dose antidepressant clinical trials: an analysis of the food and drug administration summary basis of approval reports.
    Khan A, Khan SR, Walens G, Kolts R, Giller EL.
    Neuropsychopharmacology; 2003 Mar; 28(3):552-7. PubMed ID: 12629536
    [Abstract] [Full Text] [Related]

  • 40. Methylphenidate in mild depression: a double-blind controlled trial.
    Mattes JA.
    J Clin Psychiatry; 1985 Dec; 46(12):525-7. PubMed ID: 3905773
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 26.